Effects of Rosuvastatin Calcium on insulin resistance of the flying personnel with metabolic syndrome

Objective To investigate the effects of Rosuvastatin Calcium on insulin resistance (IR) in the flying personnel with metabolic syndrome (MS). Methods Sixty-five cases of flying personnel with metabolic syndrome were assigned to group A (32 cases) and group B (33 cases) according to double blind and control method. Group A was administered with Rosuvastatin Calcium (10 mg/d) while group B was ingested by placebo (10 mg/d) with dinner. Homeostasis model assessment insulin resistance index (HOMA-IR) and drug adverse reactions of 2 groups were observed and compared before and 4 weeks after the treatment. Results There was no significant difference in the level of HOMA-IR, fasting insulin (FINS) and fasting blood glucose (FBG) between group A and group B before treatment (P>0.05). After 4-week treatment, HOMA-IR, FINS and FBG of group A was significantly lower than that of group B (t=2.895-3.231, P 0.05). There was significant difference of HOMA-IR, FBG in each group after treatment (t=4.228-8.846, P 0.05). FINS and FBG were positively correlated with HOMA-IR (r=0.436-0.982, P 0.05). Flying personnel of group A and group B were well tolerated to the treatments of Rosuvastatin Calcium. Glutamic-pyruvic transaminase, creatinine and creatine kinase had no significant difference by the treatment (P>0.05). Conclusions Rosuvastatin Calcium could improve IR in the flying personnel with MS. It is suggested that healthy lifestyle should be build and Rosuvastatin Calcium would be taken for the flying personnel with MS to effectively improve their IR if necessary. Key words: Insulin; Metabolic syndrome X; Rosuvastatin calcium; Flying personnel